Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study

Miriam Nickel, Alessandro Simonati, David Jacoby, Susanne Lezius, Dirk Kilian, Benjamin Van de Graaf, Odelya E. Pagovich, Barry Kosofsky, Kaleb Yohay, Matthew Downs, Peter Slasor, Temitayo Aiayi, Ronald Crystal, Alfried Kohlschütter, Dolan Sondhi, Angela Schulz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients. Methods: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression—measured by the rate of decline in motor and language summary scores (on a scale of 0–6 points)—and time from first symptom to death. Findings: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0–38·5) at first clinical symptom, 37·0 months (IQR 35·0 −42·0) at first seizure, and 54·0 months (IQR 47·5–60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70%]), language difficulty (42 [57%]), motor difficulty (30 [41%]), behavioural abnormality (12 [16%]), and dementia (seven [9%]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95% CI 1·50–2·12) was seen in motor–language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years. Interpretation: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies. Funding: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.

Original languageEnglish
JournalThe Lancet Child and Adolescent Health
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Observational Studies
Disease Progression
Cohort Studies
Ceroid
Language
Seizures
Hope
Complex Partial Epilepsy
National Institutes of Health (U.S.)
Datasets
Natural History
Age of Onset
Dementia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology

Cite this

Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease : an observational cohort study. / Nickel, Miriam; Simonati, Alessandro; Jacoby, David; Lezius, Susanne; Kilian, Dirk; Van de Graaf, Benjamin; Pagovich, Odelya E.; Kosofsky, Barry; Yohay, Kaleb; Downs, Matthew; Slasor, Peter; Aiayi, Temitayo; Crystal, Ronald; Kohlschütter, Alfried; Sondhi, Dolan; Schulz, Angela.

In: The Lancet Child and Adolescent Health, 01.01.2018.

Research output: Contribution to journalArticle

Nickel, M, Simonati, A, Jacoby, D, Lezius, S, Kilian, D, Van de Graaf, B, Pagovich, OE, Kosofsky, B, Yohay, K, Downs, M, Slasor, P, Aiayi, T, Crystal, R, Kohlschütter, A, Sondhi, D & Schulz, A 2018, 'Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study', The Lancet Child and Adolescent Health. https://doi.org/10.1016/S2352-4642(18)30179-2
Nickel, Miriam ; Simonati, Alessandro ; Jacoby, David ; Lezius, Susanne ; Kilian, Dirk ; Van de Graaf, Benjamin ; Pagovich, Odelya E. ; Kosofsky, Barry ; Yohay, Kaleb ; Downs, Matthew ; Slasor, Peter ; Aiayi, Temitayo ; Crystal, Ronald ; Kohlschütter, Alfried ; Sondhi, Dolan ; Schulz, Angela. / Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease : an observational cohort study. In: The Lancet Child and Adolescent Health. 2018.
@article{997a5c87695b4988a0c14a477e649d0c,
title = "Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study",
abstract = "Background: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients. Methods: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression—measured by the rate of decline in motor and language summary scores (on a scale of 0–6 points)—and time from first symptom to death. Findings: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0–38·5) at first clinical symptom, 37·0 months (IQR 35·0 −42·0) at first seizure, and 54·0 months (IQR 47·5–60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70{\%}]), language difficulty (42 [57{\%}]), motor difficulty (30 [41{\%}]), behavioural abnormality (12 [16{\%}]), and dementia (seven [9{\%}]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95{\%} CI 1·50–2·12) was seen in motor–language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years. Interpretation: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies. Funding: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.",
author = "Miriam Nickel and Alessandro Simonati and David Jacoby and Susanne Lezius and Dirk Kilian and {Van de Graaf}, Benjamin and Pagovich, {Odelya E.} and Barry Kosofsky and Kaleb Yohay and Matthew Downs and Peter Slasor and Temitayo Aiayi and Ronald Crystal and Alfried Kohlsch{\"u}tter and Dolan Sondhi and Angela Schulz",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S2352-4642(18)30179-2",
language = "English",
journal = "The Lancet Child and Adolescent Health",
issn = "2352-4642",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease

T2 - an observational cohort study

AU - Nickel, Miriam

AU - Simonati, Alessandro

AU - Jacoby, David

AU - Lezius, Susanne

AU - Kilian, Dirk

AU - Van de Graaf, Benjamin

AU - Pagovich, Odelya E.

AU - Kosofsky, Barry

AU - Yohay, Kaleb

AU - Downs, Matthew

AU - Slasor, Peter

AU - Aiayi, Temitayo

AU - Crystal, Ronald

AU - Kohlschütter, Alfried

AU - Sondhi, Dolan

AU - Schulz, Angela

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients. Methods: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression—measured by the rate of decline in motor and language summary scores (on a scale of 0–6 points)—and time from first symptom to death. Findings: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0–38·5) at first clinical symptom, 37·0 months (IQR 35·0 −42·0) at first seizure, and 54·0 months (IQR 47·5–60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70%]), language difficulty (42 [57%]), motor difficulty (30 [41%]), behavioural abnormality (12 [16%]), and dementia (seven [9%]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95% CI 1·50–2·12) was seen in motor–language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years. Interpretation: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies. Funding: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.

AB - Background: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. We aimed to analyse the characteristics and rate of progression of CLN2 disease in an international cohort of patients. Methods: We did an observational cohort study using data from two independent, international datasets of patients with untreated genotypically confirmed CLN2 disease: the DEM-CHILD dataset (n=74) and the Weill Cornell Medical College (WCMC) dataset (n=66). Both datasets included quantitative rating assessments with disease-specific clinical domain scores, and disease course was measured longitudinally in 67 patients in the DEM-CHILD cohort. We analysed these data to determine age of disease onset and diagnosis, as well as disease progression—measured by the rate of decline in motor and language summary scores (on a scale of 0–6 points)—and time from first symptom to death. Findings: In the combined DEM-CHILD and WCMC dataset, median age was 35·0 months (IQR 24·0–38·5) at first clinical symptom, 37·0 months (IQR 35·0 −42·0) at first seizure, and 54·0 months (IQR 47·5–60·0) at diagnosis. Of 74 patients in the DEM-CHILD dataset, the most common first symptoms of disease were seizures (52 [70%]), language difficulty (42 [57%]), motor difficulty (30 [41%]), behavioural abnormality (12 [16%]), and dementia (seven [9%]). Among the 41 patients in the DEM-CHILD dataset for whom longitudinal assessments spanning the entire disease course were available, a rapid annual decline of 1·81 score units (95% CI 1·50–2·12) was seen in motor–language summary scores from normal (score of 6) to no function (score of 0), which occurred over approximately 30 months. Among 53 patients in the DEM-CHILD cohort with available data, the median time between onset of first disease symptom and death was 7·8 years (SE 0·9) years. Interpretation: In view of its natural history, late-infantile CLN2 disease should be considered in young children with delayed language acquisition and new onset of seizures. CLN2 disease has a largely predictable time course with regard to the loss of language and motor function, and these data might serve as historical controls for the assessment of current and future therapies. Funding: EU Seventh Framework Program, German Ministry of Education and Research, EU Horizon2020 Program, National Institutes of Health, Nathan's Battle Foundation, Cures Within Reach Foundation, Noah's Hope Foundation, Hope4Bridget Foundation.

UR - http://www.scopus.com/inward/record.url?scp=85049315671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049315671&partnerID=8YFLogxK

U2 - 10.1016/S2352-4642(18)30179-2

DO - 10.1016/S2352-4642(18)30179-2

M3 - Article

C2 - 30119717

AN - SCOPUS:85049315671

JO - The Lancet Child and Adolescent Health

JF - The Lancet Child and Adolescent Health

SN - 2352-4642

ER -